InVitria's Cellastim Delivers Superior Results in Mammalian Cell Culture

For Immediate Release
9/25/08

Fort Collins, CO. Steve Pettit, Director of the company's Cell Culture Group, presented results of InVitria's (www.InVitria.com) Cellastim in mammalian cell culture at the 2008 BioProcess International Conference in Anaheim, California this week.

"Cellastim showed superior results compared to other sources of albumin and delivered an average of 50% improvement in productivity in CHO cell lines using variety of the leading chemically defined and animal free medias sold in the US," said Dr. Steve Pettit, Director of InVitria's Cell Culture Group.

Studies support InVitria's claim that its Cellastim product, an animal free recombinant human serum albumin, outperforms other chemically defined cell culture ingredients and is gaining acceptance by the biopharmaceutical industry as a supplement for cell culture media. Cellastim is a defined supplement that can enhance performance of chemically-defined media.

Additionally, InVitria's Lacromin product, which is an animal free recombinant lactoferrin, has proven to be a strong growth factor while simultaneously enhancing productivity across many cell lines.

"We continue to show powerful results of Cellastim and Lacromin in cell culture media for a variety of cell lines including CHO, Hybridoma, Vero and NS0 cells. Since these are well defined supplements, they help our customers achieve both their regulatory and manufacturing goals. These are the only supplements available that not only improve cell culture performance, but do this while maintaining a defined and animal free media," said Scott Deeter, InVitria's President.

To obtain a copy of Dr. Pettit's presentation please contact InVitria by phone or email at:
1-800-916-8311
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

About InVitria (www.InVitria.com)
InVitria has developed animal free cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry.